Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086086
Status:
COMPLETED
Last Update Posted:
2017-02-09
First Post:
2004-06-23
Brief Title:
Subcutaneous SC Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure CHF Anemia
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Double-blind Randomized Placebo-controlled Multicenter Study to Evaluate the Effects of Treatment With 2 Regimens of Subcutaneous Darbepoetin Alfa Weight-based Dosing and Fixed Dosing on Hemoglobin Concentration Response in Subjects With Symptomatic CHF and Anaemia
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate whether weight-based or fixed starting doses result in comparable hemoglobin increases and treatment effects in patients with heart failure and anemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None